A retrospective, observational study assessing effectiveness and safety of direct oral anticoagulants(DOACs)among nonvalvular atrial fibrillation (NVAF) patients with multimorbidity
Latest Information Update: 03 Jul 2021
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Embolism; Stroke
- Focus Adverse reactions; Therapeutic Use
- 03 Jul 2021 New trial record
- 17 May 2021 Results presented at the 70th Annual Scientific Session of the American College of Cardiology